Cyteph Announces Participation at International Society for Cell & Gene Therapy (ISCT) Annual Conference in Paris

Abstract entitled ‘Off-the-shelf CAR T cell immunotherapy for glioblastoma’ selected for Elevator Pitch Presentation on May 31, 2023

Invited participation in Asia Pacific Industry Committee (APAC) Roundtable entitled ‘Maximizing CGT Product Value: Why You Shouldn’t Overlook APAC’ on June 3, 2023

Cyteph, an Australian biotechnology company developing off-the-shelf T cell and CAR T cell therapies, announced today that lead scientist Dr Paulo Martins will present results from preclinical studies on CYT-AT1 – a novel allogeneic, dual targeting CMV EphA3 CAR T cell therapy, which shows potential for treating solid tumours, including the challenging glioblastoma multiforme (GBM). 

CYT-AT1 is the first asset in development using Cyteph's innovative Cytomegalovirus Allogeneic Tumour Targeting CAR T cell platform, known as 'Cyt-ATTAC'. Preclinical studies have demonstrated that EphA3 CAR T cells are highly effective in targeting patient-derived neurospheres and infiltrating, desegregating and killing GBM-derived organoids. EphA3 CAR T cells can be expressed on CMV-specific T cells and demonstrate dual-targeting potential against EphA3 and CMV antigens.

The Cyteph team has successfully generated EphA3 CAR T cells and these effector cells selectively kill EphA3+ GBM cell lines in vitro. Furthermore, these effector cells demonstrated curative efficacy in an orthotopic xenograft model of GBM.

In addition, Cyteph Founder and Distinguished Scientist (QIMR Berghofer), Professor Rajiv Khanna has also been invited to participate in the Asia Pacific Industry Committee Roundtable Forum at the ISCT conference.

This Roundtable Forum will focus on:

(1) Recognising the significance of the APAC region and the opportunity for earlier market approvals to your overall global product program value

(2) Understanding the key considerations for establishing an APAC Strategy to be compliant for both intra-APAC INDs and approvals as well as compliance for regulatory submissions from the US and EU

(3) Considering how an APAC Strategy impacts partnering: both in-licensing and out-licensing for global development and commercialisation

Cyteph CEO, Dr Melissa Knight, will also be in attendance to participate in key partnering and investor meetings on behalf of the Company during a critical phase of its clinical and commercial development.



300 Herston Road
Herston 4006 QLD Australia